PATENT CLAIM ANALYSIS

Application Number: 16219735
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-08
Patent Classification: ["514", "080000"]

Abstract:
The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein R A , R B , R C , R D , and R E  are defined herein.

Claim (Index 80):
The method according to  claim 78 , wherein said KRAS mutation is G12C, G12R, G12V or G13D.

Metadata:
- Claim Count in Document: 110.0
- Percentile: 98.0
- Lexical Diversity: 1.32432
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15691408', '14305393', '11487884', '12669843', '14982127']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7904107585733694
- 35 USC 102 Novelty (BERT): 0.5752928204547575
- Combined Prediction Score: 0.7688989647615083
- Mean Citation Score: 379.887276
- Max Citation Score: 539.0189
- Similarity Product: 331.5917276094675

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test